{
    "SPADE_UN_19438": {
        "Sequence Information": {
            "Peptide Name": "RGD-Temporin-La",
            "Sequence": "RGDLLRHVVKILEKYL",
            "Sequence Length": 16,
            "Biological Activity": [
                "Anticancer",
                "Anti-Mammalian Cell"
            ],
            "Binding Target": "1. Lipid Bilayer",
            "Source": "",
            "Gene": "",
            "PDB ID": "",
            "UniProt Entry": [
                {
                    "uniprotId": "C4N9P6",
                    "uniprotUrl": "http://www.uniprot.org/uniprot/C4N9P6",
                    "description": "The amino acid sequence of the current peptide coincides with the part of the UniProt entry that may represent a peptide precursor."
                }
            ],
            "Literature": [
                {
                    "Title": "Designed synthetic analogs of the ?-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin ?v?3 homing domain.",
                    "Pubmed ID": "22641352",
                    "Reference": "J Pept Sci. 2012;18:476-486",
                    "Author": "Diao Y, Han W, Zhao H, Zhu S, Liu X, Feng X, Gu J, Yao C, Liu S, Sun C, Pan F",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/22641352"
                }
            ],
            "Mass": 1952.35,
            "PI": 9.7,
            "Net Charge": 3,
            "Hydrophobicity": -0.04,
            "Frequent Amino Acids": "LKR",
            "Absent Amino Acids": "ACFMNOPQSTUW",
            "Basic Residues": 5,
            "Acidic Residues": 2,
            "Hydrophobic Residues": 7,
            "Polar Residues": 9,
            "Positive Residues": 5,
            "Negative Residues": 2,
            "SPADE ID": "SPADE_UN_19438",
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_N_05099",
                    "Similarity": 1.0,
                    "Sequence": "MSKLPFEKELKEACSKPTLTQRETALIELVGKLQNALVDSNWDKLIAEQELEYAEERLTSVVWEKRRLERGDL"
                },
                {
                    "SPADE_ID": "SPADE_N_10808",
                    "Similarity": 1.0,
                    "Sequence": "VERIPLVRFKSIKKQLHERGDL"
                },
                {
                    "SPADE_ID": "SPADE_UN_19438",
                    "Similarity": 1.0,
                    "Sequence": "RGDLLRHVVKILEKYL"
                }
            ],
            "Hemolytic Activity": "Human hepatocyte cells HL-7702 (L02):36.25±5.39% Inhibition=50 µg/ml,Human embryonic kidney HEK293T cells:27.86±4.26% Inhibition=50 µg/ml,Bovine mammary epithelial cells:19.76±8.65% Inhibition=50 µg/ml,Human PBMC:16.22±3.64% Inhibition=50 µg/ml",
            "Target Organism": "Human colon adenocarcinoma SW1116(70-80% Inhibition=50µg/ml),Human hepatocarcinoma SMMC-7721(70-80% Inhibition=50µg/ml),Human cervical carcinoma HeLa(70-80% Inhibition=50µg/ml),Human hepatocellular carcinoma HepG2(60-70% Inhibition=50µg/ml),Human gastric cancer BGC-823(60-70% Inhibition=50µg/ml),Human lung carcinoma A549(40-50% Inhibition=50µg/ml)"
        }
    }
}